NAD+ IV vs IM vs SubQ: Is More Really Better?

When most people first encounter NAD+ outside of a laboratory setting, it is often through intravenous infusion. IV NAD+ has become almost synonymous with the wider NAD+ conversation, with clinics offering large infusions administered slowly over several hours. On the surface, the reasoning seems straightforward. If NAD+ is the molecule of interest, delivering hundreds of milligrams directly into the bloodstream must surely be the most effective way to do it.

But that assumption raises an interesting question. When dealing with cellular metabolism, does delivering more of something at once necessarily mean that more of it will ultimately be utilised?

Nicotinamide adenine dinucleotide, or NAD+, is a coenzyme involved in some of the most fundamental biochemical reactions occurring within our cells. It participates in redox reactions associated with energy metabolism and is also consumed by enzymes involved in cellular signalling and other processes. Its relationship with mitochondrial metabolism is one reason NAD+ biology has attracted so much scientific interest.

However, there is an important distinction between administering NAD+ and understanding what subsequently happens to it. Putting 750 milligrams into an IV bag tells us precisely how much NAD+ entered that bag. It does not tell us that 750 milligrams subsequently entered cells intact, reached mitochondria, or was utilised in the manner we might hope.

One of the more interesting human experiments in this area investigated exactly what happened during a six-hour intravenous NAD+ infusion. Eight participants received 750 mg of NAD+ at a continuous rate of approximately 2 mg per minute. Researchers then monitored NAD+ and several related metabolites in plasma and urine throughout the infusion.

What they observed was fascinating.

For at least the first two hours, NAD+ was being infused continuously yet researchers detected no significant increase in plasma NAD+ or the metabolites they were measuring. Their results suggested that NAD+ entering the circulation during this early period was being rapidly removed from plasma through uptake and metabolism.

As the infusion continued, however, the pattern changed. Plasma NAD+ eventually increased substantially, and by the six-hour point urinary excretion of NAD+ had increased by 538% relative to the early measurement. Urinary excretion of the NAD+ metabolite methyl-nicotinamide also increased substantially.

That doesn't mean researchers discovered a precise point at which the mitochondria became “full.” There is currently no established human mitochondrial ceiling where we can confidently say that everything above a particular NAD+ dose becomes useless. Biology is far more complicated than that.

What the experiment does show is that the body's handling of a continuous NAD+ infusion changes over time. Initially, incoming NAD+ disappeared rapidly from plasma. Later in the infusion, circulating NAD+ increased and more NAD+-related material appeared in urine.

That should make us cautious about assuming that increasing an IV dose indefinitely must produce a proportional increase in useful cellular exposure.

It also introduces the question of efficiency.

IV NAD+ isn't simply a large dose of NAD+. It is an entire delivery process. Intravenous administration requires equipment, clinical supervision and time, and NAD+ infusions can run for several hours. Consequently, the final cost of an IV session can be dramatically greater than the raw cost of the molecule being administered.

There are circumstances throughout medicine where that additional complexity is entirely worthwhile because intravenous administration provides something other routes cannot. But the mere fact that something is delivered intravenously doesn't automatically make it biologically superior.

This is where intramuscular and subcutaneous administration become interesting from a research perspective.

Subcutaneous administration works very differently from an IV. Rather than introducing a compound directly into circulating blood, it deposits material into the subcutaneous tissue beneath the skin. The injection site effectively becomes a temporary depot from which material can subsequently move into systemic circulation.

It is a fundamentally different delivery profile.

An IV can be thought of as immediate access to the circulation. Subcutaneous administration is better thought of as creating a reservoir from which absorption occurs over time.

That distinction matters because peak concentration isn't necessarily the only variable worth studying. Duration of exposure, rate of absorption, frequency of exposure and total systemic availability can all matter when investigating a molecule's pharmacology.

There is also an obvious practical difference. Subcutaneous administration does not require an intravenous line or a prolonged infusion. From a research-design perspective, it therefore opens the possibility of investigating smaller repeated exposures rather than concentrating a very large amount into an occasional several-hour infusion.

Intramuscular administration provides another approach.

With IM administration, material is deposited into skeletal muscle. Muscle contains an extensive vascular network, allowing injected compounds to move from the injection depot into the systemic circulation. In general pharmacology, IM administration can produce different absorption characteristics from SubQ administration because muscle and subcutaneous tissue differ considerably in their vascularity and structure.

Again, however, NAD+ deserves an important qualification. We do not currently have robust human head-to-head pharmacokinetic research establishing exactly how equivalent NAD+ doses compare when administered intravenously, intramuscularly and subcutaneously.

That means claims that IM or SubQ NAD+ has a particular percentage bioavailability, produces superior mitochondrial uptake, or is definitively more effective than IV NAD+ would currently be difficult to substantiate.

But the absence of that evidence cuts both ways.

There is also insufficient evidence to assume that a massive IV infusion is automatically the superior approach simply because it produces direct bloodstream delivery.

Perhaps this is where the NAD+ conversation has become slightly distracted by numbers. A 750 mg or 1,000 mg infusion sounds inherently more substantial than a much smaller quantity. Bigger numbers are easy to market. They create an intuitive impression that more material must produce a greater biological effect.

Cells don't necessarily operate according to that logic.

NAD+ exists within a constantly changing metabolic network. It is synthesised, consumed, recycled, compartmentalised and metabolised. The concentration measured in plasma is not synonymous with the concentration inside a cell, and neither measurement automatically tells us what is occurring inside individual mitochondria.

So rather than asking how much NAD+ can physically be administered in one sitting, perhaps the more useful question is how different patterns of exposure affect NAD+ metabolism over time.

A large IV infusion represents one extreme: immediate vascular delivery followed by continuous administration of a comparatively large quantity.

IM represents a tissue depot within highly vascularised muscle.

SubQ represents another depot within the tissue beneath the skin, generally associated with a more gradual absorption pathway.

None should automatically be declared the winner without comparative data. But when cost, complexity and convenience are considered alongside the limited IV pharmacokinetic evidence we currently have, the assumption that IV must always be the gold standard becomes much harder to defend.

The published IV experiment is particularly thought-provoking in this respect. During the beginning of the infusion, the body appeared capable of rapidly removing incoming NAD+ from plasma. As administration continued, however, NAD+ began accumulating in plasma and urinary NAD+ excretion increased dramatically.

That doesn't prove the later portion of the infusion was “wasted.” Urinary excretion alone cannot tell us that. But it does demonstrate why simply equating a larger administered dose with proportionally greater utilisation is problematic.

And that may ultimately be where IM and SubQ NAD+ become most interesting to researchers.

Their appeal isn't that science has already proven them superior to IV administration. It hasn't.

Their appeal is that they allow a fundamentally different question to be investigated: instead of administering a very large amount during a single prolonged infusion, what happens when NAD+ is delivered from a tissue depot using smaller, repeated exposures?

That question remains surprisingly underexplored.

For now, IV NAD+ has the advantage of being the route for which we have at least some direct human metabolic data. But that research also gives us reason to question the idea that bigger intravenous doses must automatically be better.

IM and SubQ administration offer simpler delivery models without the infrastructure and prolonged administration associated with an IV infusion. Whether those differences ultimately translate into superior NAD+ pharmacokinetics or mitochondrial availability remains to be established through proper comparative research.

Until that research arrives, perhaps the most scientifically useful position is also the simplest.

The goal shouldn't necessarily be to administer the largest amount of NAD+ possible.

It should be to understand how much is actually being utilised, how quickly it is being delivered, where it ultimately goes, and whether a different delivery pattern could accomplish the same research objective more efficiently.

Because when it comes to NAD+, more isn't necessarily the most interesting question.

How it's delivered might be.

Click HERE to continue your research

References

1. Grant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, Watson J. (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience, 11:257.
   Frontiers — full study
   PubMed record
2. Covarrubias AJ, Perrone R, Grozio A, Verdin E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 22, 119–141. This is a strong general reference for NAD+ metabolism, consumption, recycling, compartmentalisation and its relationship with mitochondrial biology.
   Nature Reviews Molecular Cell Biology
3. Rajman L, Chwalek K, Sinclair DA. (2018). Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metabolism, 27(3), 529–547. Useful background for NAD biology and the important distinction between administering NAD-related compounds and demonstrating intracellular biological effects.
   Cell Metabolism article
4. TGA — Therapeutic Goods Administration (2026). Making NAD, NADH or NMN representations for listed medicines. This isn't a scientific source for the pharmacology, but it's important for how we word an Australian ÈLEVA article and avoid turning research discussion into therapeutic advertising.
   TGA NAD guidance

This article is provided for research and educational purposes only. It discusses NAD+ pharmacology and administration routes and does not provide medical advice, dosing instructions or recommendations for treatment or personal use.